Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Implementation of Motor Function Measure score percentile curves - Predicting motor function loss in Duchenne muscular dystrophy.
Hafner P, Schmidt S, Schädelin S, Rippert P, Hamroun D, Fabien S, Henzi B, Putananickal N, Rubino-Nacht D, Vuillerot C, Fischer D; MFM registry Study Group. Hafner P, et al. Among authors: rubino nacht d. Eur J Paediatr Neurol. 2022 Jan;36:78-83. doi: 10.1016/j.ejpn.2021.11.004. Epub 2021 Dec 14. Eur J Paediatr Neurol. 2022. PMID: 34929615 Free article.
Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis.
Schmidt S, Hafner P, Klein A, Rubino-Nacht D, Gocheva V, Schroeder J, Naduvilekoot Devasia A, Zuesli S, Bernert G, Laugel V, Bloetzer C, Steinlin M, Capone A, Gloor M, Tobler P, Haas T, Bieri O, Zumbrunn T, Fischer D, Bonati U. Schmidt S, et al. Among authors: rubino nacht d. Neuromuscul Disord. 2018 Jan;28(1):16-23. doi: 10.1016/j.nmd.2017.10.003. Epub 2017 Nov 21. Neuromuscul Disord. 2018. PMID: 29174526 Clinical Trial.
Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Henzi BC, Schmidt S, Nagy S, Rubino-Nacht D, Schaedelin S, Putananickal N, Stimpson G; North Star Consortium; Amthor H, Childs AM, Deconinck N, de Groot I, Horrocks I, Houwen-van Opstal S, Laugel V, Lopez Lobato M, Madruga Garrido M, Nascimento Osorio A, Schara-Schmidt U, Spinty S, von Moers A, Lawrence F, Hafner P, Dorchies OM, Fischer D. Henzi BC, et al. Among authors: rubino nacht d. Lancet Neurol. 2023 Oct;22(10):890-899. doi: 10.1016/S1474-4422(23)00285-5. Lancet Neurol. 2023. PMID: 37739572 Clinical Trial.